New eye scan may spot glaucoma before vision loss begins
NCT ID NCT02710916
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a high-resolution eye scan called SD-OCT can diagnose glaucoma more accurately than standard methods. Researchers compared 109 people with and without glaucoma using the scan. The goal was to see if this technology could catch the disease earlier, before permanent vision damage occurs.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- SD-OCT Spectralis imaging device
- What this could lead to
- If successful, this could lead to earlier and more accurate glaucoma diagnosis, potentially preventing vision loss.
- What could go wrong
- This is a completed observational study, not a treatment trial. The results may not change current practice without further validation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
109 people
The number who actually took part.
- Started
-
Feb 2016
- Finished
-
Dec 2018
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Normal Subjects 1. No history or evidence of retinal pathology or glaucoma 2. Normal Humphrey 24-2 Visual Field (VF) : A mean defect (MD), corrected pattern standard deviation (CPSD) within 95% limits of normal reference, and glaucoma hemifield test (GHT) within normal limits (97%). 3. Intraocular pressure \< 21 mm Hg 4. Open angle (Shaffer's grading system) 5. Normal appearing Optic Nerve Hypoplasia (ONH) and Nerve Fiber Layer (NFL) : intact neuroretinal rim without peripapillary hemorrhages, notches, localized pallor, or NFL defect 6. Symmetric ONH between left and right eyes: Cup-to-Disc Ratio (CDR) difference \< 0.2 in both vertical and horizontal dimensions Inclusion Criteria: Perimetric Glaucoma 1. ONH or NFL defect visible on slit-lamp biomicroscopy defined as one of following: * diffuse or localized thinning of the rim * disc (splinter) hemorrhage * notch in the rim * vertical cup/disc ratio greater than the fellow eye by \> 0.2 2. Consistent glaucomatous pattern on both qualifying Humphrey Swedish Interactive Threshold Algorithm (SITA) 24-2 VF meeting at least one of the following quantitative criteria for abnormality: * PSD outside normal limits (p \< 0.05) * GHT outside normal limits (p \< 0.01) Inclusion Criteria: Pre-Perimetric Glaucoma (PPG) PPG participants must have at least one eye meeting all of the following criteria: 1. ONH or NFL defect visible on slit-lamp biomicroscopy defined as one of following: * diffuse or localized thinning of the rim * disc (splinter) hemorrhage * notch in the rim * well-defined peripapillary NFL bundle defect. * inter-eye vertical CDR asymmetry \> 0.2 2. Baseline VF not meeting the criteria for the PG group. 3. Risk factors for glaucoma, one of following: * Intraocular pressure \> 21 mm Hg * Ethnics * Family history of glaucoma Exclusion Criteria: All Groups 1. Age \< 40 2. Refractive error of \> +6.00 D or \< -6.00 D (SE), +3,00 D for astigmatism 3. Diabetic retinopathy 4. Other diseases that may cause VF loss or optic disc abnormalities 5. Inability to clinically view or photograph the optic discs due to media opacity or poorly dilating pupil 6. Inability to perform reliably on automated VF testing 7. Insufficient quality of Spectralis OCT images (this is not determined until after Spectralis OCT examination, and is an unusual circumstance). Minimum requirements are: * Retina completely included in image frame, * Quality Score ≥ 15 in the stored mean images, 8. Refusal of informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Eye diseases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Bordeaux Hospital
Bordeaux, Aquitaine, 33000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can exercise shield the eyes of glaucoma patients?
- The 20-Minute squeeze: how eye injections push pressure up
- Can better Follow-Up schedules save sight in glaucoma?
- Portable devices could take the guesswork out of eye pressure checks
- Eye drops may shield the cornea after cataract surgery
- Can a puff of air replace the eye pressure probe?